4BB 4basebio Plc

 
TIDM4BB 
 
9 February 2023 
 
                                 4basebio plc 
                         ("4basebio" or the "Company") 
 
 
                    Exercise of Options and Issue of Equity 
 
4basebio plc (AIM: 4BB), the specialist life sciences group focused on 
exploiting intellectual property in the field of cell and gene therapies and 
DNA vaccines, announces that it has received a notification from an employee to 
exercise options over 2,000 ordinary shares ("New Ordinary Shares") in the 
Company at an exercise price of 118 pence per share for total proceeds of £ 
2,360. 
 
Following this exercise of options, the Company has options outstanding over 
710,500 ordinary shares in aggregate, representing approximately 5.77 per cent. 
of the Company's enlarged issued share capital following admission of the New 
Ordinary Shares. 
 
Admission to AIM 
 
Application will be made for the New Ordinary Shares to be admitted to trading 
on AIM ("Admission"). It is expected that Admission will become effective at 
8.00 a.m. on or around 14 February 2023. The New Ordinary Shares will be issued 
credited as fully paid and will rank in full for all dividends and other 
distributions declared, made or paid after Admission and will otherwise rank on 
Admission pari passu in all respects with the existing ordinary shares. 
 
Total Voting Rights 
 
Following Admission, the total number of ordinary shares in issue will be 
12,319,473. The Company does not hold any ordinary shares in treasury. 
Therefore, the total number of ordinary shares with voting rights will be 
12,319,473. This figure may be used by shareholders in the Company as the 
denominator for the calculations by which they will determine if they are 
required to notify their interest in, or a change to their interest in, the 
share capital of the Company under the Financial Conduct Authority's Disclosure 
and Transparency Rules. 
 
This announcement contains inside information for the purposes of Article 7 of 
EU Regulation 596/2014. 
 
For further information please contact: 
 
4basebio plc                                            +44 (0)12 2396 7943 
 
Heikki Lanckriet, CEO 
 
Cairn Financial Advisers LLP (Nominated                 +44 (0)20 7213 0880 
Adviser) 
 
Jo Turner / Sandy Jamieson 
 
finnCap Ltd (Broker)                                    +44 (0)20 7220 0500 
 
Geoff Nash/Richard Chambers/Charlotte 
Sutcliffe 
 
 
 
 
END 
 
 

(END) Dow Jones Newswires

February 09, 2023 02:00 ET (07:00 GMT)

4basebio (LSE:4BB)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024

4basebio (LSE:4BB)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024